文献速递消化道肿瘤放疗放疗物理与技术

NF-κB调控的miR-221/222/Syndecan-1轴与放射性肠炎肠黏膜屏障功能

The NF-κB-Regulated miR-221/222/Syndecan-1 Axis and Intestinal Mucosal Barrier Function in Radiation Enteritis.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-01-13

研究纳入21例放疗期间发生放射性肠炎的宫颈癌患者,检测炎症反应和屏障功能,并在照射的胎儿人结肠细胞及诱导小鼠放射性肠炎模型中验证。结果显示肠炎患者存在肠黏膜屏障破坏;Sdc1过表达可逆转TEER抑制、抑制FD4通量并上调ZO-1和occludin;机制上照射激活P65直接结合启动子区增加miR-221/222转录,后者结合Sdc1基因3‘非翻译区抑制其转录后表达。结论提示Sdc1在NF-κB和miR-221/222转录调控下保护屏障功能并控制炎症,可能成为抗放射性肠炎新靶点。

要点

  • 放射性肠炎患者肠黏膜存在明显炎症损伤和屏障破坏,血清LPS、LBP和细胞因子水平升高,尿乳果糖/甘露醇比值升高。
  • 照射的胎儿人结肠细胞中过表达Sdc1可逆转TEER抑制、抑制FD4通量并上调ZO-1和occludin表达。
  • 机制为照射激活P65直接结合启动子区增加miR-221/222转录,miR-221/222结合Sdc1基因3’非翻译区抑制其转录后表达。

核心结论

  • 研究提示Sdc1在NF-κB通路和miR-221/222的转录调控下保护放射性肠炎中的屏障功能并控制炎症。
  • NF-κB、miR-221/222和Sdc1组成的网络在放射性肠炎发病机制中起重要作用,Sdc1可能成为新型抗放射性肠炎策略的治疗靶点。

研究设计与样本

  • 收集21例放疗期间发生放射性肠炎的宫颈癌患者的血液、尿液和组织样本,检测炎症反应和屏障功能。
  • 在照射的胎儿人结肠细胞和诱导的小鼠放射性肠炎模型中检测Sdc1在屏障功能中的作用。
  • 通过Western blotting和染色质免疫沉淀检测NF-κB-P65通路的作用,通过实时聚合酶链反应和荧光素酶报告基因实验评估miR-221/222的作用。

主要发现

  • 放射性肠炎患者肠黏膜存在明显的病理和超微结构炎症损伤及屏障破坏,血清LPS、LPS结合蛋白和细胞因子水平升高,尿乳果糖/甘露醇比值升高。
  • 在照射的胎儿人结肠细胞中过表达Sdc1可逆转TEER抑制、抑制FD4通量并上调ZO-1和occludin表达。
  • 在放射性肠炎小鼠中补充外源性低分子量肝素可改善肠炎活动性和屏障缺陷。
  • 机制上,照射激活的P65通过直接结合启动子区增加miR-221/222转录,miR-221/222随后通过结合Sdc1基因3‘非翻译区在转录后抑制Sdc1基因。

关键数值与推荐

  • 屏障功能通过ZO-1和occludin表达、TEER和FD4通量测定。
  • NF-κB-P65通路通过Western blotting和染色质免疫沉淀检测。
  • miR-221/222的作用通过实时聚合酶链反应和荧光素酶报告基因实验评估。

临床怎么用

  • 原文结论未据此给出推荐。
  • 作者认为Sdc1可能成为新型抗放射性肠炎策略的治疗靶点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation enteritis (RE) is the most common complication of pelvic radiation therapy, but proven therapies are lacking. Barrier function defects are closely associated with numerous inflammatory disorders. In this study, we investigated whether barrier dysfunction contributes to RE and whether syndecan-1 (Sdc1) protects intestinal barrier function in RE. The mechanism was also elucidated. METHODS AND MATERIALS: Blood, urine, and tissue samples were collected from 21 patients with cervical cancer who experienced RE during radiation therapy. The samples were used to detect inflammatory responses and barrier function. The role of Sdc1 in barrier function was examined in cultured fetal human colon (FHC) cells exposed to radiation and an induced mouse RE model. Barrier function was determined by zonula occludens (ZO)-1 and occludin expression, transepithelial electrical resistance (TEER), and fluorescein isothiocyanate-dextran (FD4) flux. The role of the nuclear factor (NF)-κB-P65 pathway was detected by Western blotting and chromatin immunoprecipitation. The role of miR-221/222 was assessed by real-time polymerase chain reaction and luciferase reporter assays. RESULTS: Patients with RE exhibited obvious pathologic and ultramicrostructural inflammatory injury and barrier disruption in the intestinal mucosa, as well as higher serum lipopolysaccharide (LPS), LPS-binding protein, and cytokine levels and a higher urine lactulose-to-mannitol ratio. Overexpression of Sdc1 in irradiated FHC cells reversed TEER suppression, repressed FD4 flux, and upregulated ZO-1 and occludin expression. Exogenous low-molecular-weight heparin supplementation in RE mice ameliorated the activity of enteritis and barrier defects. Mechanistically, irradiation-activated P65 increased the transcription of miR-221/222 via direct binding to the promoter regions, and miR-221/222 then posttranscriptionally suppressed the Sdc1 gene by binding to its 3'-untranslated region. CONCLUSIONS: The findings suggest that Sdc1 protects barrier function and controls inflammation during RE under transcriptional regulation by the NF-κB pathway and miR-221/222. The network including NF-κB, miR-221/222, and Sdc1 is important in the pathogenesis of RE, and Sdc1 might represent a therapeutic target for novel anti-RE strategies.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Wang Z, Wang Q, Gong L, et al. The NF-κB-Regulated miR-221/222/Syndecan-1 Axis and Intestinal Mucosal Barrier Function in Radiation Enteritis. Int J Radiat Oncol Biol Phys. 2022. PMID: 35033585. doi:10.1016/j.ijrobp.2022.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。